An Overview on GPCRs and Drug Discovery: Structure-Based Drug Design and Structural Biology on GPCRs
Year: 2009
Type: book-chapter
Abstract: The drug discovery process has passed through dramatic changes during the past 20 years. The requirements for drug manufacturing and especially the safety aspects related to the final medicine have become immense. This development has made the drug discovery and development processes both time-consuming and labor intensive. Not surprisingly, development of drugs has become extremely expensive. In addition, the success rate of bringing new successful drugs to the market has been worryingly low. One approach to speed up drug discovery and also to reduce the adverse effects of developed drugs has been to apply structure-based drug design. There are a number of examples of success. For instance, structural information has played an important role in lead optimization in drug screening programs ( 1 ) . Furthermore, high-resolution structures of HIV proteinase ( 2 ) and influenza virus neuraminidase ( 3 ) have contributed directly to the development of AIDS (Agenerase® and Viracept®) and flu (Relenza®) drugs, respectively. In total, more than 10 drugs can today be considered as designed based on known high-resolution structures of target molecules.
Source: Methods in molecular biology
Author: Kenneth Lundstrom
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W35537551